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OBJECTIVE—This study was conducted to investigate the association of diabetic peripheral
neuropathy (DPN) with both arterial stiffness and intima–media thickness (IMT).
RESEARCHDESIGNANDMETHODS—Weconductedacross-sectionalanalysisof731
subjects with type 2 diabetes. DPN was diagnosed on the basis of neuropathic symptoms, in-
sensitivity to a 10-g monoﬁlament, abnormal pin-prick sensation, and abnormal current per-
ceptionthreshold.Arterialstiffnesswasassessedbycardio-anklevascularindex(CAVI),andIMT
was assessed by B-mode ultrasonography.
RESULTS—Patients with DPN had higher CAVI than those without DPN in multivariate-
adjusted models, whereas no differences in IMT were observed between patients with and
withoutDPNafteradjustmentforageandsex.Inthemultivariateanalysis,CAVIwasasigniﬁcant
determinant of DPN (odds ratio 1.36 [95% CI 1.13–1.65], P = 0.001).
CONCLUSIONS—DPN is signiﬁcantly associated with arterial stiffness without carotid in-
timal changes in patients with type 2 diabetes.
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T
he leading cause of death in patients
with diabetes is cardiovascular dis-
ease (CVD) (1); recent studies have
reported that microvascular disease is
also associated with excess mortality (2).
Although the underlying mechanism is
unclear, some evidence suggests that the
effects of microvascular disease on mor-
tality may be linked to subclinical athero-
sclerosis,consideringatheroscleroticvascular
changes in parallel with microvascular
complications, including retinopathy (3),
nephropathy(4),andautonomicneurop-
athy (5).
Diabetic peripheral neuropathy (DPN)
is a common microvascular complication
with high mortality rates (6), but little is
known about the association between
DPN and atherosclerotic vascular changes.
Thus, we investigated the association be-
tween DPN and vascular wall properties
inpatientswith type 2 diabetes bymeasur-
ingcardio-anklevascularindex(CAVI)and
carotid intima–media thickness (IMT).
RESEARCH DESIGN AND
METHODS—We retrospectively re-
cruited subjects with type 2 diabetes,
aged 20–80 years, who visited Seoul
St. Mary’s hospital between May 2008
and June 2009. Subjects were excluded
if they had peripheral vascular disease;
an ankle-brachial pressure index ,0.9;
or severe illness, such as acute infectious
disease,progressivemalignancy,orsevere
renal impairment.
DPN was diagnosed in subjects dis-
playing two or more of the following
features: neuropathic symptoms, insensi-
tivity to a 10-g monoﬁlament, abnormal
pin-prick sensation, and abnormal cur-
rent perception threshold (CPT). Neuro-
pathic symptoms were assessed by a total
symptom score, CPT using a Neurometer
CPT/C (Neurotron, Inc., Baltimore, MD),
and autonomic neuropathy by heart rate
variability totheValsalvamaneuver, deep
breathing, and standing (7).
CAVI was measured using a CAVI-
VaSera VS-1000 (Fukuda Denshi, Tokyo,
Japan),asdescribedpreviously(8).Carotid
IMT was measured using high-resolution
B-mode ultrasonography (Logiq S6, Gen-
eralElectricMedicalSystems,Wauwatosa,
WI) in 681 subjects. The average IMT
value on one side was calculated, and the
thicker of the sides was used for analysis.
Comparisons were made using the
Student t test or x
2 test. ANCOVA was
used to compare CAVI and IMT. Logistic
regression analyses were performed to es-
timate the odds ratios (ORs) and 95% CIs
for DPN or abnormal CAVI. A P value ,
0.05 was considered to indicate statistical
signiﬁcance.
RESULTS—Of the 731 subjects (aged
57.5 6 11.2 years), 127 (17.4%) were di-
a g n o s e dw i t hD P N .S u b j e c t sw i t hD P N
were older, had a longer duration of di-
abetes, had higher systolic blood and
pulse pressure, and were more likely to
have albuminuria and retinopathy than
subjects without neuropathy. However,
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Pathophysiology/Complications
BRIEF REPORTsubjects with DPN had a lower glomeru-
lar ﬁltration rate, HDL cholesterol level,
and BMI (Supplementary Table A1). No
difference in glycosylated hemoglobin
(HbA1c) or fasting glucose levels was ob-
servedbetweensubjectswithandwithout
DPN.
CAVI was signiﬁcantly higher in sub-
jects with DPN than in subjects without
DPN, after adjusting for age, sex, diabetes
duration, BMI, HbA1c, pulse pressure,
glomerularﬁltrationrate,hyperlipidemia,
CVD, autonomic neuropathy, and use of
insulin or antihypertensive drugs (8.87
vs. 8.45, P = 0.001). In contrast, the dif-
ference in IMT between the groups lost
signiﬁcance after adjusting for age and
sex. In multivariate logistic regression
models, CAVI was a signiﬁcant predictor
ofDPN(OR1.36[95%CI1.13–1.65],P=
0.001, Table 1).
Moreover, subjects with DPN had an
OR for abnormal CAVI of 2.54 (95% CI
1.52–4.26, P , 0.001) after adjusting for
confoundingfactors.Theassociationwith
abnormalCAVIremainedsigniﬁcantafter
further adjusting for microvascular com-
plications and even in subgroups divided
by age, BMI, diabetes duration, and hy-
pertension (Supplementary Table A2).
CONCLUSIONS—We showed that
DPN was closely associated with CAVI
independently of traditional cardiovascu-
lar risk factors. DPN remained a signiﬁ-
cant determinant of abnormal CAVI after
further adjusting for other microvascular
complications and was signiﬁcant in sub-
groups classiﬁed by age, BMI, diabetes
duration, and hypertension.
Several studies have reported an in-
creased risk for CVD and other microvas-
cular diseases, including retinopathy and
microalbuminuria (3–5,9). However,
only two reported studies have investi-
gated associations between DPN and
CVD risk (9,10). Yokoyama et al. (10)
found that diabetic neuropathy was asso-
ciated with arterial stiffness assessed by
brachial-ankle pulse-wave velocity in
294 patients with type 2 diabetes. How-
ever, in contrast with our study, they
observed a positive relationship between
DPN and IMT.This inconsistency may be
due to different sample sizes and the di-
agnostic criteria they used (they included
cases of autonomic neuropathy). Another
study by Cardoso et al. (9), conducted on
482 patients with type 2 diabetes, also
demonstrated a close relationship be-
tween DPN and aortic stiffness.
The signiﬁcant association between
DPN and increased CAVI observed in this
study suggests that determinants of CVD
principally affecting arterial stiffness may be
potential risk factors for DPN. Accordingly,
prospective cohort studies have demon-
strated that CVD risk factors predict the
development of DPN in patients with type
1 diabetes (11,12). Although the underly-
ingmechanismlinkingDPNtoarterialstiff-
ness is not well understood, one possible
explanationisthatlargearterystiffnessmay
cause microvascular damageviahighpulse
pressure,leadingtodiminishedblood ﬂow
tonervetissuesvulnerabletohypoxicdam-
age, and thereby to the development of
neuropathy (13).
It is beyond the scope of this study to
establish whether increased arterial stiff-
ness is a causal risk factor for DPN or a
concomitant ﬁnding developed by shared
pathogenic mechanisms. Nevertheless,
our results have clinical implications.
Patients with DPN are at high risk of
CVD because of their increased arterial
stiffness (14) whether it has causal as-
sociation or not. Therefore, careful as-
sessment of the combined risks and
intensive intervention may reduce the
risk of CVD.
A major limitation of our study is its
cross-sectionaldesign; thus,we could not
determine temporal or causal relation-
ships between DPN and arterial stiffness.
Another limitation is that the study sub-
jects may not represent the general pop-
ulation.
In conclusion, DPN is signiﬁcantly
associated with arterial stiffness without
changes in IMT in patients with type 2
diabetes. Further prospective studies
could elucidate whether intensive man-
agement of CVD risk factors other than
glycemiccontrolcanalsopreventordelay
the development of neuropathy.
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